Form 4 for EOG EOG Resources
Accepted 2023-03-14 00:00:00 ET · period of report 2023-03-10 · accession 0001209191-23-018385 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-14 | 2023-03-10 | EOG | Yacob Ezra Y | COB, CEO, Dir | D - Sale to Iss | $113.96 | -31.9K | 117.6K | -21% | -$3.63M |
| DM | 2023-03-14 | 2023-03-10 | EOG | Yacob Ezra Y | COB, CEO, Dir | F - Tax | $113.96 | -5,887 | 116.0K | -5% | -$670.9K |
| DM | 2023-03-14 | 2023-03-10 | EOG | Yacob Ezra Y | COB, CEO, Dir | M - OptEx | $77.55 | +46.8K | 119.2K | +65% | +$3.63M |
| DM | 2023-03-14 | 2023-03-10 | EOG | Yacob Ezra Y | COB, CEO, Dir | M - OptEx | $0.00 | -46.8K | 3,016 | -94% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-10 | D | D | 1,396 | $113.96 | 117,770.36 | D | — | — | |
| 2 | Common | Common Stock | 2023-03-10 | D | D | 9,136 | $113.96 | 120,653.36 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-10 | F | D | 1,412 | $113.96 | 119,241.36 | D | — | — | |
| 4 | Common | Common Stock | 2023-03-10 | F | D | 706 | $113.96 | 117,064.36 | D | — | — | |
| 5 | Common | Common Stock | 2023-03-10 | M | A | 12,725 | $81.81 | 129,789.36 | D | — | — | |
| 6 | Common | Common Stock | 2023-03-10 | M | A | 15,870 | $96.29 | 126,039.36 | D | — | — | |
| 7 | Common | Common Stock | 2023-03-10 | D | D | 13,410 | $113.96 | 112,629.36 | D | — | — | |
| 8 | Common | Common Stock | 2023-03-10 | F | D | 968 | $113.96 | 111,661.36 | D | — | — | |
| 9 | Common | Common Stock | 2023-03-10 | M | A | 9,029 | $75.09 | 120,690.36 | D | — | — | |
| 10 | Common | Common Stock | 2023-03-10 | D | D | 5,950 | $113.96 | 114,740.36 | D | — | — | |
| 11 | Common | Common Stock | 2023-03-10 | F | D | 1,212 | $113.96 | 113,528.36 | D | — | — | |
| 12 | Common | Common Stock | 2023-03-10 | M | A | 6,013 | $37.44 | 119,541.36 | D | — | — | |
| 13 | Common | Common Stock | 2023-03-10 | D | D | 1,976 | $113.96 | 117,565.36 | D | — | — | |
| 14 | Common | Common Stock | 2023-03-10 | F | D | 1,589 | $113.96 | 115,976.36 | D | — | — | |
| 15 | Common | Common Stock | 2023-03-10 | M | A | 3,190 | $49.86 | 119,166.36 | D | — | — | |
| 16 | Derivative | Stock Appreciation Rights | 2023-03-10 | M | D | 3,190 | $0.00 | 1,600 | D | $49.86 · 2022-01-04 to 2028-01-04 | 3,190 Common Stock | (F4) The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the January 4, 2021 date of grant. The SARs granted will become fully exercisable on January 4, 2024. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 17 | Derivative | Stock Appreciation Rights | 2023-03-10 | M | D | 12,725 | $0.00 | 25,489 | D | $81.81 · 2022-09-27 to 2028-09-27 | 12,725 Common Stock | (F5) The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 27, 2021 date of grant. The SARs granted will become fully exercisable on September 27, 2024. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 18 | Derivative | Stock Appreciation Rights | 2023-03-10 | M | D | 15,870 | $0.00 | 0 | D | $96.29 · 2018-09-25 to 2024-09-25 | 15,870 Common Stock | (F1) The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 25, 2017 date of grant. The SARs granted became fully exercisable on September 25, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 19 | Derivative | Stock Appreciation Rights | 2023-03-10 | M | D | 9,029 | $0.00 | 0 | D | $75.09 · 2020-09-26 to 2026-09-26 | 9,029 Common Stock | (F2) The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 26, 2019 date of grant. The SARs granted became fully exercisable on September 26, 2022. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 20 | Derivative | Stock Appreciation Rights | 2023-03-10 | M | D | 6,013 | $0.00 | 3,016 | D | $37.44 · 2021-09-28 to 2027-09-28 | 6,013 Common Stock | (F3) The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 28, 2020 date of grant. The SARs granted will become fully exercisable on September 28, 2023. This exercise did not involve any open-market sale of the Issuer's Common Stock. |